Healthcare Business Recap: Cell Therapeutics POPS, Merck’s GLOWING Prospects

Shares of Cell Therapeutics, Inc. (NASDAQ:CTIC) go through the roof, following Tuesday’s announcement of the strt of its commercial intro of Pixuvri in the European Union, which is a medication for the treatment of aggressive non-Hodgkin Lymphoma.

Merck & Co.’s (NYSE:MRK) promising new products such as Suvorexant, along with a strong dividend yield of 3.8 percent, should have investors buying shares for some time to come, according to Barron’s. Further, decreases in headcount plus synergies from its purchase of Schering-Plough have boosted the firm’s margin and growth outlook. Investors might also appreciate the double-digit profit and operating margins, and a healthy balance sheet.

The FDA’s rejection of Navidea Biopharmaceuticals’ (NYSE:NAVB) Lymphoseek application along with the lack any of visibility on an FDA reviewing process going forward, has pounded its shares, prompting ThinkEquity to downgrade the shares to Hold. The firm also slashes its price target from $7 to $2.50 in the process.

Are these stocks a buy or sell? Let us help you decide. Check out our Wall St. Cheat Sheet Stock Picker Newsletter now >>